Drug intelligence / Profile preview

Addumedrol-4

Development stage: Unknown
Lead developer: ADDUCO RBS
Modality: Small Molecules
Administration: Oral

Overview

Addumedrol-4 is an oral small molecule formulation of methylprednisolone developed by ADDUCO RBS. Methylprednisolone is a synthetic glucocorticoid known for its potent anti-inflammatory and immunosuppressive properties. Addumedrol-4 is approved for the treatment of various anti-inflammatory conditions and is designed to provide a specific dosage (likely 4 mg) using ADDUCO RBS's oral delivery technology. As a glucocorticoid receptor agonist, the active ingredient binds to cytosolic receptors, translocates to the nucleus, and modulates gene transcription to inhibit the production of inflammatory cytokines and mediators while inducing the expression of anti-inflammatory proteins.

Brand names: Addumedrol-4Addumedrol4Addumedrol 4
Other names: methylprednisolone

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Addumedrol-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Addumedrol-4.

Explore the full profile